Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2002

View Archived Issues

ImClone Systems and Bristol-Myers Squibb revise Erbitux agreement

Onyx and Proacta to collaborate on therapeutic virus research and development

Fujirebio Diagnostics acquires rights to develop cancer diagnostics using Survivin gene

AtheroGenics begins phase I trial of transplant rejection drug AGI-1096

Encouraging results of DCVax-Prostate in late-stage prostate cancer

Ionix and Xenome collaborate on analgesic drug discovery

Institut Pasteur to evaluate Novirio compounds for hemorrhagic fever viruses

AltaRex initiates OvaRex pharmacokinetic study

Actonel found to be equieffective in weekly or daily doses in postmenopausal women

Lundbeck drops potential anxiolytic from pipeline

Cipralex/Lexapro heads for major launches by mid-2002

Allopurinol exerts immunomodulating effects in experimental autoimmune uveitis

Once-daily ravuconazole effective and safe in Rx of onychomycosis

Safety of repinotan demonstrated in subjects with severe traumatic brain injury

European phase II pancreatic adenocarcinoma trial of investigational camptothecin derivative reports

Clinical results for efalizumab in plaque psoriasis constitute a highlight of the AAD meeting

The Medicines Company acquires rights to clevidipine

Researchers at Zentaris describe novel series of antitumor agents

CPMP recommends expansion of desloratadine indication to indoor and outdoor allergies

Additional trial requested for sNDA of Thalomid in early stage multiple myeloma

FDA finds Soltara not approvable

Thirty-six new products reach their first markets in 2001

Chugai identifies coumarin derivatives useful as TNF-alpha inhibitors

Nucleoside analogues and their use as antiviral agents reported

Compounds that inhibit cholesterol biosynthesis and their uses claimed by Boehringer Ingelheim

Lundbeck patents novel inhibitors of glycine transporters

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...